The treatment of choice for the failure to restore neurogenic bladder dysfunction, managed with clean intermittent catheterization program with incontinence, is anticholinergic medication. The goal is to increase bladder capacity, and decrease intravesical pressure in order to maintain continence between catheterizations. The most commonly used anti cholinergic medication in the United States is Oxybutynin. Previous clinical studies have shown that 61 % of the patients on oral Oxybutynin report adverse systemic side effects and are noncompliant in taking it. In 48% of the yatients, possibly due to their noncompliance, oral Oxybutynin Hydrochloride is ineffective. l • In this study, 13 spinal cord injured patients with a failure to restore bladder dysfunction were treated with intravesical Oxybutynin. Nine patients improved on the regimen while one patient underwent surgical bladder augmentation. Postoperatively, this patient continued to be incontinent between catheterizations. Reinstitution of intravesical Oxybutynin stabilized the patient's bladder with clean intermittent catheterization without further intervention.
Introduction
Voiding dysfunction can pose a difficult management problem in clinical care. The storage and elimination of urine depends on a complex central control system that coordinates autonomic and somatic efferent activity to various effector organs (the bladder, the urethra and the striated muscles of the pelvic floor). There are three major muscle structures responsible for the storage and the elimination of urine from the bladder.
The detrusor muscle receives primarily parasympa thetic cholinergic innervation; the external sphincter muscle has sympathetic, parasympathetic and somatic fibers; and the bladder outlet or 'internal sphincter' receives mainly alpha-adrenergic sympathetic innerva tion. Activation of the parasympathetic pathways of the detrusor via the parasympathetic pathways and inhibition of the internal urethral sphincter via the somatic input are essential neural events initiating the release of the urine. Activation of the detrusor muscle occurs via a spino-bulbo-spinal pathway. Relaxation of the urinary sphincter is produced by inhibitory mechanisms in the sacral spinal cord. 3 , 4 Urodynamic studies measure bladder capacity,
Correspondence: SM SzolJar bladder volume at the first urge to void and the leak point pressure. There are two major bladder dysfunc tions based on urodynamic studies: failure to empty and failure to store. 5 The management of choice for the failure to empty bladder dysfunction is clean intermittent catheteriza tion (CIC). Patients with failure to store bladder dysfunction experience urgency (in case of incomplete spinal cord injury), frequency and incontinence due to the small bladder capacity. It can occur due to increased detrusor activity or decreased outlet resistance. On urodynamic studies, this bladder has a capacity of less than 300 cc. The first urge to void appears at a volume of less than 150 cc, when the leak point pressure is 45 cmH20. Patients will often restrict their fluid intake and decrease their social activity. The prolonged high pressure on the upper urinary tracts may result in renal function deterioration. The treatment is aimed to decrease intravesical pressure and increase bladder capacity, thus, creating a large capacity bladder which can be managed with CIC. The medical treatment of choice is anticholinergic medica tion. Oxybutynin Hydrochloride is one of the most commonly used medications in the United States. The maximum recommended dose is 5 mg three times/day. Its usefulness is limited by its side effects: xerostomia and constipation. 6 In case of failure of the medical management, surgical intervention with bladder augmentation is the alternative treatment to restore upper urinary tracts.
Methods
Thirteen patients with failure to store neurogenic bladder dysfunction on CIC were included in the study. Selection criteria were poor tolerance to oral Oxybutynin and/or unsatisfactory response. Poor tolerance was defined as the inability to tolerate 5 mg Oxybutynin three times/day, which is the maximum recommended oral dose. Unsatisfactory response was defined as incontinence on the maximum recommended oral dose. The selection criteria for the clean intermittent catheterization program was adequate dexterity and cognitive function. The mean age of the patients was 41 years with a range of 20-68 years. Levels of spinal cord injury ranged from C5 to Ll. The main interval after injury was 8.7 years and ranged from one year to 26 years. Baseline laboratory studies included: serum creatinine, BUN, 24 h urine creatinine clearance, upper tract imaging and videourodynamic studies. Videourodynamic studies were performed utilizing a Life Tech Model 1406 machine. A 9F dual lumen urethral catheter was utilized. The needle electrode was positioned in the external sphincter muscle under transrectal ultrasound guidance. The abdominal pressure was monitored with a rectal balloon. The bladders were filled with 14% Conray contrast at 50 ml/min. Detrusor pressure, intraabdom inal pressure, subtracted detrusor pressure, and sphincter activity was recorded. If all of the baseline laboratory tests, except videourodynamic studies, were within normal limits the patients were offered inclusion in the study. The patients who agreed to participate were instructed to dilute 5 mg crushed Ditropan in 30 ml saline solution and to instill the solution into the bladder following catheterization three times/day. The Oxybutynin was left in the bladder until the next catheterization. Clinical progress was monitored with scheduled outpatient clinic visits. At the end of 3 months on the regimen, videourodynamic studies were repeated.
For statistical analysis, paired samples of t test were used.
Results
69% of the patients included in the study reported continence. 50% of the patients who failed to respond to oral Oxybutynin Hydrochloride reported continence. 80% of the patients who were converted to instillation because of poor tolerance reported continence. The instillation's were tolerated well. One patient required surgical bladder augmentation due to failure to respond to intravesical Oxybutynin Hydrochloride. Following augmentation cystoplasty he continued to significant. The decrease in leak point pressure, which is the most crucial parameter to monitor in protecting upper urinary tract function, was found to be statistically significant.
Discussion
Oxybutynin Hydrochloride is a synthetic tertiary amine which is chemically and pharmacologically similar to some antispasmodic local anesthetics and antihistamine compounds. It exerts a direct spasmolytic action and an antimuscarinic (atropine-like) action on smooth muscle. The spasmolytic effect of the drug has been demonstrated on the detrusor muscle of the bladder, the small intestine and the colon. In animal studies, the drug has shown moderate antihistaminic, some local anesthetic, mild analgesic, midriatic, and antisiologo gue activity. Studies using radio labeled oxybutynin indicate that the drug undergoes enterohepatic circula tion and is excreted in urine and feces. It is widely used to treat detrusor instability. Its effectiveness is limited by intolerance to oral administration, due to systemic side effects. In an effort to mitigate the side effects associated with oral anticholinergic agents and provide another option to patients who would otherwise be offered an augmentation cystoplasty, attention has focused on the use of intravesical agents to treat failure to store bladder dysfunction. The studies reported in the literature 7 -13 examined the short-term response to intravesical oxybutynin, and only one examined long term effects. 14 All of the investigators claimed to have less systemic side effects with intravesical oxybutynin than with oral administration. It has been theorized that intravesical oxybutynin is not absorbed into the bloodstream, and its efficacy results from a profound local effect alone. 
